Heat Biologics CEO to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 21, 2021

Rhea-AI Summary

Heat Biologics (NASDAQ:HTBX) announced that its CEO, Jeff Wolf, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on January 21, 2021, at 11:30 a.m. EST. The presentation will be available via live webcast for registered conference attendees and institutional investors. A replay will be accessible on Heat's website shortly after the event. Heat Biologics is focused on developing first-in-class therapies to modulate the immune system, with its gp96 platform targeting cancer and COVID-19.

DURHAM, NC / ACCESSWIRE / January 20, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference.

The Heat's presentation will be webcast live at 11:30 a.m. EST on Thursday, January 21, 2021. The presentation will be open to registered conference attendees, institutional investors and investor relations professionals, who may register to view the live webcast at https://b-riley-oncology-investor-conference.events.issuerdirect.com/signup. After completion of the event, a replay of the presentation will be publicly available under the "Investors - News/Events" tab on the Heat Biologics website at www.heatbio.com.

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The Company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which is enrolling in a Phase 1 trial.

Media and Investor Relations Contact

David Waldman
+1 919 289 4017
investorrelations@heatbio.com

SOURCE: Heat Biologics, Inc.

View source version on accesswire.com:
https://www.accesswire.com/624982/Heat-Biologics-CEO-to-Participate-in-a-Fireside-Chat-at-the-B-Riley-Securities-Oncology-Investor-Conference-on-Jan-21-2021

FAQ

When will Heat Biologics CEO Jeff Wolf speak at the B. Riley Securities conference?

Jeff Wolf will participate in a fireside chat on January 21, 2021, at 11:30 a.m. EST.

How can I watch the Heat Biologics presentation at the oncology conference?

You can watch the live webcast by registering at https://b-riley-oncology-investor-conference.events.issuerdirect.com/signup.

What is the main focus of Heat Biologics?

Heat Biologics focuses on developing therapies to modulate the immune system, including oncology products and a COVID-19 vaccine.

What technology does Heat Biologics use for its therapies?

Heat Biologics uses the gp96 platform to activate immune responses against cancer and pathogens.

Where can I find the replay of the Heat Biologics presentation?

A replay will be available on Heat Biologics' website under the 'Investors - News/Events' tab after the conference.